An Pham, MD
Pulmonary Disease · Pottstown, PANPI 1609848456
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 1,643 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $6,587, 2.1 times the $3,163 reported in 2019. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,643 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- GSK$3K
- Actelion Pharmaceuticals US, Inc.$3K
- Sanofi$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Jazz Pharmaceuticals Inc.$1K
- plus $16K from 43 others
Across 16 payments — averaging $8844.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$88K
- GSK$28K
- Sanofi US Services Inc.$26K
What the payments were for
- Consulting fees$6902%
- Speaking & faculty fees$1000%
- Food & beverage$31,04095%
- Education$9503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,779 in reported general payments places this provider in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 49 | $699,977 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 856 | $664,726 |
| OfevNintedanib Esylate | 26 | $346,180 |
| EsbrietPirfenidone | 30 | $301,260 |
| UptraviSelexipag | 14 | $294,364 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 323 | $243,690 |
| XolairOmalizumab | 68 | $202,159 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $114,594 |
| Pirfenidone | 25 | $81,288 |
| Spiriva RespimatTiotropium Bromide | 109 | $76,626 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 142 | $75,897 |
| Breo ElliptaFluticasone/Vilanterol | 138 | $74,552 |
| FasenraBenralizumab | 11 | $59,105 |
| NucalaMepolizumab | 13 | $48,160 |
| SymbicortBudesonide/Formoterol Fumarate | 112 | $32,497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $2,633 | $994,34163 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta | $2,947 | $886,8311,212 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,389 | $460,749195 claims |
| AstraZenecaBreztri Aerosphere, Fasenra, Symbicort | $5,654 | $335,292446 claims |
| Genentech USA, Inc.Esbriet | $539 | $301,26030 claims |
| Axsome Therapeutics, Inc.Sunosi | $533 | $20,96121 claims |
| PfizerEliquis | $869 | $18,23822 claims |
| MerckBelsomra, Dulera | $180 | $11,41126 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $17 | $6,50413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Pottstown
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.